key: cord-0336447-gran7fta authors: Ibarrondo, F. J.; Hofmann, C.; Ali, A.; Ayoub, P.; Kohn, D. B.; Yang, O. O. title: Previous Infection Combined with Vaccination Produces Neutralizing Antibodies With Potency Against SARS-CoV-2 Variants date: 2021-08-29 journal: nan DOI: 10.1101/2021.08.27.21262744 sha: c9a877dfa90ef1e9af27faa54818357c9944143c doc_id: 336447 cord_uid: gran7fta SARS-CoV-2 continues to evolve in humans. Spike protein mutations increase transmission and potentially evade antibodies raised against the original sequence used in current vaccines. Our evaluation of serum neutralizing activity in both persons soon after SARS-CoV-2 infection (in April 2020 or earlier) or vaccination without prior infection confirmed that common spike mutations can reduce antibody antiviral activity. However, when the persons with prior infection were subsequently vaccinated, their antibodies attained an apparent biologic ceiling of neutralizing potency against all tested variants, equivalent to the original spike sequence. These findings indicate that additional antigenic exposure further improves antibody efficacy against variants. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 29, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. As SARS-CoV-2 evolves to become better suited for circulating in humans, mutations have 63 occurred in the spike protein it uses for attaching to cells it infects. Protective antibodies from 64 prior infection or vaccination target the spike protein to interfere with its function. These 65 mutations can reduce the efficacy of antibodies generated against the original spike sequence, 66 raising concerns for re-infections and vaccine failures, because current vaccines contain the 67 original sequence. In this study we tested antibodies from people infected early in the pandemic 68 (before spike variants started circulating) or people who were vaccinated without prior infection. 69 We confirmed that some mutations reduce the ability of antibodies to neutralize the spike 70 protein, whether the antibodies were from past infection or vaccination. Upon retesting the 71 previously infected persons after vaccination, their antibodies gained the same ability to 72 neutralize mutated spike as the original spike, suggesting that the combination of infection and 73 vaccination drove the production of enhanced antibodies to reach a maximal level of potency. 74 Whether this can be accomplished by vaccination alone remains to be determined, but the results 75 suggest that booster vaccinations may help improve efficacy against spike variants. 76 77 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 29, 2021. were not yet reported to circulate, and all had mild infection that did not require hospitalization. after 48 hours. The Hill equation was utilized to estimate the dilution factor yielding 80% 120 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 29, 2021. proposed by that report, additional maturation due to vaccination, or both. In contrast to studies 183 showing ongoing affinity maturation, a recent report suggests that potency declines after 184 resolution of infection [7], suggesting that vaccination has a key role in this phenomenon. 185 Finally, the apparent ceiling for antiviral potency against all tested variants is consistent with 186 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. eventually also applies to the tested variants. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 29, 2021. Detection of a SARS-CoV-2 variant of concern 241 in South Africa Genomics and epidemiology of the P.1 SARS-CoV-243 2 lineage in Manaus, Brazil Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma 246 antibodies Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine 248 against the B.1.351 Variant Evidence for increased breakthrough rates of SARS-CoV-2 250 variants of concern in BNT162b2-mRNA-vaccinated individuals Antibodies in Persons with Mild Covid-19 Recall, and Decay Kinetics of SARS CoV-2 Vaccine Antibody Responses A serological assay to detect SARS-CoV-2 256 seroconversion in humans SARS-CoV-2 Seroconversion in Humans: A 258 No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Effectiveness of the BNT162b2 Covid-19 Vaccine 263 against the B.1.1.7 and B.1.351 Variants Development of potency, breadth and resilience 265 to viral escape mutations in SARS-CoV-2 neutralizing antibodies Evolution of antibody immunity to SARS-CoV-2. 268 Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 271 variants Affinity dependence of the B cell response to antigen: a 273 threshold, a ceiling, and the importance of off-rate Early high-affinity neutralizing anti-viral IgG 275 responses without further overall improvements of affinity (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted August 29, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101/2021.08.27.21262744 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted August 29, 2021. ; https://doi.org/10.1101/2021.08.27.21262744 doi: medRxiv preprint